Sarepta (SRPT) Q4 2025 earnings review
The Growth Engine Derails: ELEVIDYS Label Contraction Triggers Massive Write-Offs
Sarepta's Q4 print is a stark reality check. Despite management touting a 'position of strength,' the numbers show a business undergoing aggressive financial repair following the June 2025 suspension of ELEVIDYS shipments for non-ambulatory patients. Total revenue fell 33% YoY, driven by a reversing trajectory in ELEVIDYS sales, which collapsed to $110.4M from $384.2M a year ago. This abrupt demand shock forced a massive $165.3M write-off for excess inventory. Combined with a $200M milestone payment for the siRNA pipeline, Q4 operating margins were decimated. While the legacy PMO franchise proved highly resilient and cost-cutting measures are taking effect, 2026 hinges entirely on whether the newly established $500M ELEVIDYS sales floor can hold and if the reprioritized pipeline can deliver.
🐂 Bull Case
The legacy exon-skipping (PMO) therapies generated stable, growing sequential revenue, acting as a vital cash generator while the company navigates the ELEVIDYS reset.
The FDA approved dosing for ENDEAVOR Cohort 8 to evaluate an enhanced immunosuppressive regimen (sirolimus). A successful outcome here is the critical catalyst to unlocking the suspended non-ambulatory market.
🐻 Bear Case
Cost of sales skyrocketed due to a $165.3M inventory valuation reserve. The company severely overproduced relative to the newly restricted label, wiping out gross margins.
ELEVIDYS volumes were further pressured by a severe year-end flu season and rescheduled patient infusions, leaving the Q4 exit velocity weak heading into 2026.
⚖️ Verdict: 🔴
Bearish. The sheer magnitude of the inventory write-offs and the continued sequential decline in the flagship gene therapy contradict management's optimistic narrative. The path to 2026 profitability requires flawless execution from a currently depressed baseline.
Key Themes
Inventory Management Contradicts 'Position of Strength'
Management claimed they entered 2026 from a 'position of strength,' but the financial data contradicts this narrative. Q4 GAAP operating loss was a staggering $411.6M. A primary driver was a $165.3M inventory valuation reserve for excess ELEVIDYS and PMO product on hand. This write-off highlights a massive miscalculation in production planning following the June label restriction, proving the supply chain was caught entirely off-guard by the demand drop.
PMO Franchise Delivers Stable Cash Flow
Despite the noise surrounding the gene therapy portfolio, the PMO franchise (EXONDYS 51, VYONDYS 53, AMONDYS 45) is stable and slightly accelerating. It accounted for 70% of Q4 net product revenues, growing sequentially to $259.2M. This durable cash flow is single-handedly funding the company's reprioritized R&D pipeline and debt obligations.
siRNA Platform Innovation Accelerating
Sarepta is aggressively pivoting its innovation engine toward the TRiM siRNA platform. The FDA approved the CTA for SRP-1005 in Huntington's disease, marking a critical leap for a technology previously shown to achieve up to 80% protein knockdown in deep brain regions of non-human primates via subcutaneous delivery. Dosing begins in Q2 2026, establishing a major new pipeline vector outside of muscular dystrophy.
Macro Tailwind: Duchenne Added to RUSP
In a significant macro development, Duchenne Muscular Dystrophy was added to the U.S. Recommended Uniform Screening Panel (RUSP). This federal designation will accelerate state-level newborn screening adoption, expanding the long-term addressable market by enabling diagnosis and intervention before the onset of irreversible muscle damage.
PMO Regulatory Overhang Lingers
While PMO sales are currently strong, a structural risk remains. The Phase III ESSENCE confirmatory trial failed to meet statistical significance on its primary endpoint (as disclosed in Q3). Sarepta's defense relies heavily on post-hoc analyses and real-world evidence. If the FDA rejects the 'totality of evidence' argument for traditional approval, the company's primary cash engine could face regulatory headwinds.
siRNA Catalyst Timelines Delayed
Initial data readouts for the highly anticipated DM1 (SRP-1003) and FSHD siRNA programs were pushed from year-end 2025 into early 2026 (announced in Q3) to allow for assay validation. While Cohort 3 of the DM1 trial is fully enrolled, the delay postpones critical proof-of-concept data needed to validate the $300M+ Arrowhead investment.
Other KPIs
Reversing trend. Driven by a $135M increase in non-GAAP R&D (largely the $200M Arrowhead milestone) and the $165M inventory reserve. This is a dramatic drop from the $207M non-GAAP net income generated in 24Q4.
Decelerating. Down from $1.50 billion at the end of 2024. The cash burn reflects the combination of lower operating cash flows, the cash portion of the 2027 convertible debt refinancing, and heavy upfront licensing payments.
Accelerating. Up from $20.3 million a year ago, primarily driven by a $45.6M increase in contract manufacturing shipments of ELEVIDYS to international partner Roche, highlighting that ex-U.S. demand remains a bright spot.
Guidance
Decelerating relative to the $898.7M achieved in FY25, but represents management's 'stress test' baseline for the strictly ambulatory population. Achieving this floor requires a slight sequential acceleration from the Q4 annualized run-rate of ~$441M.
Reversing trend vs Q4 2025. Management expects the absence of one-time inventory write-offs, the completion of massive upfront R&D milestones, and the realization of cost savings from the July 2025 restructuring (36% headcount reduction) to pull the company out of the red.
Key Questions
Inventory Expiration Risk
With the $165.3M inventory valuation reserve taken this quarter, has the risk of further ELEVIDYS batch expirations been fully cleared, or could slow onboarding in the ambulatory population trigger additional write-offs in 2026?
ENDEAVOR Cohort 8 Timelines
Now that dosing is approved for the enhanced immunosuppression regimen, what is the specific timeframe to generate the biomarker data (liver enzyme reduction) required to approach the FDA for a label expansion back into non-ambulatory patients?
Gross Margin Normalization
Excluding the one-time inventory charges, what is the expected normalized gross margin profile for ELEVIDYS in 2026 given the lower production volumes and fixed manufacturing overhead?